MIAMI BEACH, Fla., Aug. 13, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ: AIRS) ("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced that the Company will participate in the Sidoti Micro Cap Conference being held virtually from August 20 to 21, 2025. Management will meet with investors throughout both days and host a presentation at 10:00am ET on Wednesday, August 20. The presentation will be webcast live at https://investors.airsculpt.c ...

Core Insights - Cardinal Health's multi-specialty management services organization (MSO), The Specialty Alliance, is set to acquire urology MSO Solaris Health, enhancing its capabilities in the urology sector [1][3] - The acquisition will be financed by Cardinal Health providing approximately $1.9 billion in cash, resulting in Cardinal Health owning about 75% of The Specialty Alliance post-acquisition [2] - The transaction is anticipated to close by the end of the year [2] Company Expansion - The acquisition of Solaris Health will expand The Specialty Alliance's reach, building on previous acquisitions including Urology America, Potomac Urology, and Academic Urology & Urogynecology [3] - Solaris Health currently supports over 750 providers across 250 practice locations in 14 states, which will increase Cardinal Health's MSO platforms to approximately 3,000 providers in 32 states [3] Strategic Focus - Cardinal Health's CEO emphasized that accelerating specialty growth is a top priority, particularly in the urology specialty, which is viewed as attractive for the company [4] - The partnership with Solaris Health aims to enhance patient-centered care through a physician-led national platform, optimizing care delivery and improving patient access to specialized services [4] Financial Performance - Cardinal Health reported fourth quarter revenues of $60.2 billion, which remained relatively flat year over year, while fiscal year 2025 revenues were reported at $222.6 billion, reflecting a 2% decline from the previous fiscal year [5] - The company previously announced its GI Alliance MSO platform's agreements to acquire Urology America and Potomac Urology, furthering its strategy to support physician-led practices and improve patient outcomes [6]

Core Viewpoint - Nutex Health Inc. has faced significant share price decline following a critical report by Blue Orca Capital, which raised concerns about the company's practices related to independent dispute resolution vendor HaloMD and its financial health [1][5]. Group 1: Financial Impact and Investigations - Following the implementation of the No Surprises Act (NSA) on January 1, 2022, Nutex experienced a decline in average payments by insurers for emergency services, with a decrease of approximately 26% by the end of 2022 and about 19% by the end of 2023 [3][4]. - Nutex's annual report for March 31, 2025, indicated a refined estimate of revenue recognition, which increased revenue and net income before tax for the year ended December 31, 2024, by approximately $169.7 million and $112.0 million, respectively [5]. - Blue Orca's report suggested that Nutex's revenue may be largely uncollectible, highlighting a massive receivables balance of uncollected awards, which poses significant risk to the company [5]. Group 2: Legal and Regulatory Concerns - Hagens Berman, a national shareholders rights firm, has initiated an investigation into whether Nutex misled investors regarding its compliance with the NSA and the propriety of its actions [2][6]. - Blue Orca identified HaloMD, Nutex's IDR vendor, as being involved in serious legal issues, including accusations of theft, fraud, and racketeering, which could potentially implicate Nutex in future litigation [5].

The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here's the latest list of major oversold players in this sector, having an RSI near or below 30. Exact Sciences Corp EXAS The most oversold stocks in the hea ...

Core Insights - Organon (OGN) is currently more attractive to value investors compared to HealthEquity (HQY) based on various financial metrics and Zacks Rank [3][7]. Valuation Metrics - OGN has a forward P/E ratio of 2.38, significantly lower than HQY's forward P/E of 24.60 [5]. - The PEG ratio for OGN is 0.90, while HQY's PEG ratio stands at 1.18, indicating OGN's better valuation relative to its expected earnings growth [5]. - OGN's P/B ratio is 3.23, compared to HQY's P/B ratio of 3.74, further supporting OGN's more favorable valuation [6]. Zacks Rank and Style Scores - OGN holds a Zacks Rank of 2 (Buy), indicating a stronger earnings outlook, while HQY has a Zacks Rank of 3 (Hold) [3]. - OGN has a Value grade of A, whereas HQY has a Value grade of C, reflecting OGN's superior valuation metrics [6].

Group 1 - Concentra Group reported quarterly earnings of $0.37 per share, matching the Zacks Consensus Estimate, but down from $0.49 per share a year ago [1] - The company achieved revenues of $550.79 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 2.61% and up from $477.92 million year-over-year [2] - Concentra has surpassed consensus EPS estimates three times over the last four quarters [2] Group 2 - The stock has added approximately 0.8% since the beginning of the year, underperforming compared to the S&P 500's gain of 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is $0.41 on revenues of $565.74 million, and for the current fiscal year, it is $1.35 on revenues of $2.14 billion [7] - The Zacks Industry Rank indicates that the Medical Services sector is in the top 40% of over 250 Zacks industries, suggesting a favorable outlook for the industry [8]

Group 1: Earnings Performance - AMN Healthcare Services reported quarterly earnings of $0.3 per share, exceeding the Zacks Consensus Estimate of $0.17 per share, but down from $0.98 per share a year ago, representing an earnings surprise of +76.47% [1] - The company has surpassed consensus EPS estimates for the last four quarters [2] - AMN Healthcare's revenues for the quarter ended June 2025 were $658.18 million, surpassing the Zacks Consensus Estimate by 0.87%, but down from $740.68 million year-over-year [2] Group 2: Stock Performance and Market Comparison - AMN Healthcare shares have declined approximately 28% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The stock is currently rated Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Group 3: Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.19 on revenues of $639.01 million, and for the current fiscal year, it is $1.04 on revenues of $2.63 billion [7] - The outlook for the Medical Services industry, where AMN operates, is currently in the top 40% of Zacks industries, suggesting potential for better performance compared to lower-ranked industries [8]

Company Performance - Solventum (SOLV) reported quarterly earnings of $1.69 per share, exceeding the Zacks Consensus Estimate of $1.45 per share, and up from $1.56 per share a year ago, representing an earnings surprise of +16.55% [1] - The company posted revenues of $2.16 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.87%, and an increase from $2.08 billion year-over-year [2] - Over the last four quarters, Solventum has consistently surpassed consensus EPS and revenue estimates [2] Stock Performance - Solventum shares have increased approximately 9.9% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future due to unfavorable estimate revisions prior to the earnings release [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.37 on revenues of $2.11 billion, and for the current fiscal year, it is $5.58 on revenues of $8.43 billion [7] - The outlook for the Medical Services industry, where Solventum operates, is favorable as it ranks in the top 40% of over 250 Zacks industries, suggesting potential for outperformance compared to lower-ranked industries [8]

Company Performance - Ascend Wellness Holdings, Inc. reported a quarterly loss of $0.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.07, representing an earnings surprise of -71.43% [1] - The company posted revenues of $127.3 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.93% and down from $141.54 million a year ago [2] - Over the last four quarters, the company has only surpassed consensus EPS estimates once and has not beaten consensus revenue estimates [2] Stock Movement and Outlook - Ascend Wellness Holdings, Inc. shares have increased approximately 20.5% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.07 on revenues of $132.15 million, and for the current fiscal year, it is -$0.27 on revenues of $527.85 million [7] Industry Context - The Medical Services industry, to which Ascend Wellness Holdings, Inc. belongs, is currently ranked in the top 40% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact the stock's performance [5][6]

Core Insights - Aurora Cannabis reported a first-quarter fiscal 2026 loss per share of 26 cents, missing the Zacks Consensus Estimate of 18 cents per share and reversing a profit from the prior year [1][7] - The company's total net revenues reached $98 million, reflecting a year-over-year increase of 17.5% and surpassing the Zacks Consensus Estimate by 38.3% [3][7] Revenue Performance - The revenue growth was primarily driven by strong international medical cannabis sales, particularly in Australia, Germany, Poland, and the UK, alongside increased revenues in Canada [4][8] - The Global Medical Cannabis segment generated $64.8 million in revenues, up 37% year over year, making it the strongest contributor to the company's revenue [5][8] - International Medical Cannabis revenues surged 84.7% year over year to $37.1 million, while Canadian Medical Cannabis revenues increased by 2.1% to $27.7 million [8][9] Segment Analysis - Consumer cannabis revenue declined by 32% year over year to $7.9 million, as the company prioritized high-margin medical cannabis over the lower-margin consumer segment [9] - The Plant Propagation segment, primarily from the Bevo business, contributed $23.9 million, up 3.8% from the previous year [10] Financial Metrics - Gross profit decreased by 34.9% year over year to $27.9 million, but the adjusted gross margin improved by 1000 basis points to 52% [11] - Total operating expenses rose by 9.7% year over year to $48.2 million, with significant increases in general and administration expenses [11][12] Financial Position - At the end of the first quarter, Aurora Cannabis had cash and cash equivalents of $140.2 million, slightly up from $137.9 million at the end of fiscal 2025 [13] - Net cash provided by operating activities increased to $10.1 million compared to $8.3 million a year ago [13] Future Guidance - The company anticipates consolidated net revenue growth in the fiscal second quarter of 2026, with Global Medical Cannabis revenue expected to increase by 8%-12% [14] - The Plant Propagation segment is expected to align with traditional seasonal trends, with a significant portion of annual revenue typically earned in the second half of the calendar year [14][15]